Cingulate receives first U.S. patent for ADHD drug candidate CTx-1301
Go back to Cingulate receives first U.S. patent for ADHD drug candidate CTx-1301| (NASDAQ: CING) | Delayed: 4.90 -0.09 (1.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.99 | 52 Week High | $ | |||
| Open | $4.99 | 52 Week Low | $ | |||
| Day High | $5.09 | P/E | N/A | |||
| Day Low | $4.83 | EPS | $ | |||
| Volume | 165,806 | |||||
| (NASDAQ: CINGW) | Delayed: 0.02 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.02 | 52 Week High | $ | |||
| Open | $0.02 | 52 Week Low | $ | |||
| Day High | $0.02 | P/E | N/A | |||
| Day Low | $0.02 | EPS | $ | |||
| Volume | 1,036 | |||||
